A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
← catalyst calendarNCT07063745 · readout in 1,818 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
590estimated
Sites
319
Countries
Argentina, Australia, Austria +31
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-02 | actual | When the study began enrolling |
| Primary completion | 2031-08-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-08-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Interventions
- Drug: BMS-986504
- Drug: Pembrolizumab
- Other: Placebo
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: Paclitaxel
- Drug: Nab-paclitaxel
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS) by RECIST v1.1
measured Up to 2 years
PFS by RECIST v1.1 per BICR
measured Up to 5 years
Overall Survival (OS)
measured Up to 5 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed